Recruiting

Observational Study

Sponsor:

Glaukos Corporation

Code:

NCT07400926

Conditions

Open Angle Glaucoma (OAG)

Ocular Hypertension (OH)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Travoprost

Study Details

Brief summary:

Clinical in-use observational trial to evaluate the updated inserter for the Travoprost Intracameral implant using the updated inserter (Model G2-TRIO)

Conditions

Open Angle Glaucoma (OAG)

Ocular Hypertension (OH)

Study ID

NCT07400926

Start date

Dec 17, 2025

Status verified date

Feb, 2026

Completion date

Jul, 2026

Anticipated

Primary completion date

Jun, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Diagnosis of Open-angle glaucoma
  • 18 years of age or older

Exclusion Criteria:

  • Subject who is breast-feeding or pregnant

Study Design

Enrollment

30 participants

Anticipated

Interventions and Outcome Measures

Arms

Model G2-TRIO

Subjects receive a Travoprost intracameral implant with the Model G2-TRIO

Interventions

Travoprost

Travoprost intracameral implant, 75mcg administered using the sterile, single-dose updated inserter (Model G2-TRIO)

Primary outcome measure

  • Successful implantation [ Time Frame: 1 day ]

Central Contacts and Locations

Central contacts

Study Director

949-739-8749ClinicalResearch@glaukos.com

Locations

Glaukos Investigative Site

Recruiting

Kenosha, Wisconsin, United States, 53140

More Information

Sponsor

Glaukos Corporation

Last update posted

Feb 27, 2026

Last verified

Feb, 2026

Keywords

  • Glaucoma
  • Ocular Hypertension

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Glaukos Corporation on 2026-02-27.